Abiopharma

🔍 D'Angelo Scott (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-06-08

Detailed Transactions and Holdings:

• Acquired 8 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: A | equity_swap_involved: false | shares_owned_after: 5,758.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3, F4
• Acquired 3 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: A | equity_swap_involved: false | shares_owned_after: 2,399.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3, F4
• Acquired 4 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: A | equity_swap_involved: false | shares_owned_after: 2,861.00 | transaction_form_type: 4 | Footnotes: F1, F2, F5, F5, F4

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: Represents accrual of dividend equivalent rights on RSUs held by the Reporting Person.
• F3: The dividend equivalent rights accrued on RSUs held by the Reporting Person and vest proportionately with the RSUs to which they relate. The RSUs vest in three equal installments on the first, second and third anniversaries of May 1, 2025.
• F4: Includes RSUs and all dividend equivalent rights that have accrued on such RSUs to date.
• F5: The dividend equivalent rights accrued on RSUs held by the Reporting Person and vest proportionately with the RSUs to which they relate. The RSUs vest in three equal installments on the first, second and third anniversaries of April 1, 2026.